GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT

/PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics...

Related Keywords

Australia ,United States ,Sydney ,New South Wales ,United Kingdom ,California ,Melbourne ,Victoria ,Brisbane ,Queensland ,University Of California San Francisco ,Spain ,Australian ,Dan Forche ,Bruce Mann ,Prnewswire Genesiscare ,Yvonne Zissiadis ,Troy Bremer ,Instagram ,Therapeutic Goods Association ,Linkedin ,National Cancer Institute ,Prelude Corporation Preludedx ,Prelude Corporation ,Australasian International Breast Congress ,Facebook ,Breast Cancer Network Australia ,Breast Cancer Services For Royal Melbourne ,Ductal Carcinoma In Situ ,Interim Analysis ,Treatment Recommendation ,Biologic Signature Predictive ,Radiation Therapy ,Specialist Breast Surgeon ,Breast Cancer Services ,Royal Melbourne ,Royal Women ,Professor Bruce Mann ,Genesiscare Radiation Oncologist ,Chief Scientific Officer ,Cancer Network ,Clinical Utility ,Radiation Therapy Decision Making ,Ann Surg Oncol ,California San Francisco ,Medicare Benefits Scheme ,Know Your ,Decision Score ,Know Your Risk ,Genesis Care ,